Market data powered by FactSet and Web Financial Group. In rare diseases, it often takes some time for a patient to initiate treatment once they're identified, and OneSource helps support patients throughout that journey. 4Q 2020 Earnings Q&A 247 KB. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. Please take a look at the risk factors discussed in our SEC filings for additional detail. Performance in the quarter was driven by return of hospital demand and further benefited by some normalization of stocking activities. Your line is now open. We’re motley! For the Phase III study of ULTOMIRIS, can you provide an enrollment status update? So, when we look at quarter to quarter, I would not over-extrapolate what we have in this quarter or, frankly, even the next quarter. In contrast, 2050, as we've announced, is going into PNH as monotherapy. A couple of COVID-related questions, if I may. So, in the third quarter, Germany actually in Neurology, though we didn't give the specific numbers, had a very nice pop, growth in both NMOSD as well as gMG. 30 October 2020: Q3 2020 Earnings Call Transcript Q2 2020. Sure. On Slide 16, we have a view of our quarterly revenues, including the implied revenue for fourth quarter based on the midpoint of our updated 2020 guidance. My questions -- two of them for you. Turning now to Slide 20 to discuss progress made thus far in 2020 and key upcoming R&D milestones. Alexion Pharmaceuticals' (ALXN) CEO Ludwig Hantson on Q3 2020 Results - Earnings Call Transcript Oct. 29, 2020 2:35 PM ET Alexion Pharmaceuticals, Inc. (ALXN) SA Transcripts Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q1 2020 Earnings Call Transcript Alexion Pharmaceuticals (ALXN) Q1 profit drops 5% but beats estimates Alexion (ALXN) to acquire Portola (PTLA) for $1.44 billion I'll start with ANDEXXA, just in the order that you asked. Reconciliations of our financial results and financial guidance are included in our press release. Two related questions for me. While we're very pleased with our ANDEXXA progress in just a few short months and the stabilization seen in sales for the quarter, we still have a ways to go in order to maximize the opportunity in line with our ambitions. So, what we see is in the U.S., as I've mentioned, the claims for gMG have been down, not including SOLIRIS, just overall, about 20%. Should COVID persist longer into 2021, are there some new strategies that you've implemented today to help with new patient adds? AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. OK. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q3 2018 Earnings Call October 24, 2018 8:00 AM ET Executives. 6 May 2020 : Q1 2020 Earnings Call Transcript Q4 2019. To execute on this approach in hospitals, we plan to optimize both new and existing top-tier accounts. Ludwig Hantson — Chief Executive Officer. Thanks, John. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. Image source: The Motley Fool. UK: +44 203 481 5237 Sweden: +46 8 5052 0017 US: +1 301 715 8592. As we've discussed previously, we plan to refocus the allocation of commercial resources to shift to a multifaceted hospital system approach. Non-GAAP SG&A expense was $301 million or 19% of revenues. Thou,gh going forward, you know, again, our Neurology business is growing strongly in Japan, though we may have more effect from, for example, competitor trials there and so forth. ET. Listen to Webcast. We look forward to continuing to drive this momentum as the integration progresses. As we shared on our investor day earlier in October, we have made tremendous progress thus far in 2020 on our breadth of development. Thanks. 30 October 2020: Q3 2020 Earnings Call Transcript Q2 2020. If you look at our guidance for the fourth quarter, for the full year, we are definitely taking into account not only sort of the selling days and the ULTOMIRIS price headwind, but additional COVID wave, our field force in many countries, and the U.S. also remains sort of working remotely. Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q4 2019 Earnings Conference Call January 30, 2020. Brian Goff — Executive Vice President, Chief Commercial … Q4 Earnings Presentation 3.3 MB. And that really is the story within ANDEXXA. In the third quarter, we continue to build on the momentum of the last few years. Logo of jester cap with thought bubble. 4 February 2019: Q4 2018 Earnings Conference Call Transcript All call transcripts. ET. Yeah, good morning, Geoff. 6 May 2020 : Q1 2020 Earnings Call Transcript Q4 2019. In your comments about Germany, it sounded like there was some warehousing of patients during COVID that -- and there was a bolus once COVID subsided a bit and the answer to the last question, though, it sounded like you also suggested maybe some gMG patients just simply go away if they don't go on therapy immediately because there's promotional sensitivity and it's a more forgiving disease. Thank you, Brian. I am pleased to share that our ULTOMIRIS gMG trial has achieved greater than 90% enrollment, and we have closed the screening process for patients globally. Operator, we'll take the next question. Very strong data, and we agreed to the criteria with the regulatory agencies. Given the great progress John's team has made with enrollment, we anticipate a potential U.S. launch for ULTOMIRIS in gMG in the second half of 2022. Sorry, John, do you want to comment on 2040 for GA? Leonard Bell - Director and CEO. I'd like to reiterate some of the key messages from our Investor Day earlier this month. So, I do think there's a potential to grow the market. There is strong scientific rationale for blocking terminal complement supported by recent publications, where the dual mechanisms of inflammation and Mac deposition, along with the activation of the coagulation cascade, which is clearly interlinked with complement positions the C5 inhibition for success. AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 | Price: Free! Alexion Pharmaceuticals, Inc. Q3 2017 Earnings Conference - Final Transcript. The doctor then educating the patient about all the benefits of the efficacy that they've had with SOLIRIS plus every two months opportunity, which is less burdensome for them. So, we had another strong quarter. Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q1 2019 Earnings Call April 25, 2019, 8:00 a.m. Finally, the ALXN2040 PNH add-on therapy program remains on track to begin Phase III development by the end of this year. Your line is now open. [Operator instructions] Our first question comes from Josh Schimmer with Evercore ISI. And thanks for the kudos on the quarter. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. ET. There were also some experience in France as well as in the U.K. with C5 inhibition suggesting that there's a potential benefit. Turning to Slide 12. As we shared earlier this month, we have significant opportunity in our Factor D and FcRn platforms and high-value potential in our innovative assets such as CAEL-101 and 1840. ... Earnings Call Transcript Q4 2018. John Orloff — Executive Vice President and Head of Research & Development Our last question comes from the line of Geoff Meacham with Bank of America. As has been our practice recently, we are practicing physical distancing and are each doing the call from home. It's picking up now because we have growing activity with second-wave surges in U.S. as well as France and U.K. ULTOMIRIS is now established as the market leader for PNH across our top markets, with atypical HUS on track to achieve a similar outcome within two years of launch. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q4 2017 Earnings Call February 8, 2018 10:00 AM ET Executives. Alexion Pharmaceuticals (NASDAQ:ALXN)Q3 2020 Earnings CallOct 29, 2020, 8:00 a.m. We have the OneSource team, of course, with very strong patient support, particularly in the U.S. And then the thing I'm most proud of is that, in Neurology, we've got a team now that is highly experienced in both gMG as well as NMOSD with three years and counting experience. 30 January 2020: Q4 2019 Earnings Call Transcript Q3 2019. Contents: Prepared Remarks So, one on ANDEXXA. We will begin the call with a brief presentation, and we'll reserve the rest of the time for your questions. We see continued double-digit revenue growth in our portfolio, and we believe we have a clear path to $9 billion to $10 billion in revenue by 2025. Find the latest Earnings Report Date for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. And that's virtual promotional effectiveness, really healthy mix of in-person as well as virtual. I wouldn't necessarily say that the third quarter was driven by pent-up demand, though we did see some orders, as we mentioned, particularly in tender markets and certain international markets that were forecasted in fourth quarter, you know, come in the third quarter. All earnings call transcripts. Despite the challenges posed by COVID-19, the Alexion team has continued to deliver. From Alexion’s third-quarter 2020 earnings conference call: Ludwig Hantson — Chief Executive Officer. Download the investor presentation - earnings call slides. On the first one with home infusion, it's a relatively small part of overall utilization. Thanks for taking the questions, and congrats on the good quarter. Secondly, on Germany and the dynamics around gMG, Neurology, I would not characterize it as patients "go away" with gMG. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Geoffrey Porges -- SVB Leerink -- Analyst. We'll be moving into myasthenia gravis with 1720, and that's a small volume subcutaneous administration that's ideally suited for auto-injector. 30 January 2020: Q4 2019 Earnings Call Transcript Q3 2019. But, again, it's uncontrolled data. We expect year-over-year growth for the fourth quarter to be 4%, while full-year growth is expected to be 19%. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. This is Brian. And I've talked a number of times about the best way to think of the opportunity with ANDEXXA is it's a three-part story. 23 October 2019: Q3 2019 Earnings Call Transcript Q2 2019. Thank you. And given the strong value proposition of SOLIRIS, we continue to focus on driving depth of adoption with physicians who are experienced with the benefits of SOLIRIS for both gMG and NMOSD patients. Aradhana, do you want to start with the moving parts financially? We're in conversations now to see whether the same data set can support a subcu filing in myasthenia gravis and NMO. | Source: Seeking Alpha AstraZeneca's (AZN) CEO Pascal Soriot on Q3 2020 Results - Earnings Call Transcript May 5, 2020 at 8:00 AM EDT And the other point I'll just make is, it's important for this quarter to note that we've had no observable competitive impact with NMOSD to date. I have the questions -- great quarter. It seems like the guidance is still fairly conservative considering the 3Q sales of $39 million. Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. And this update reflects revenues between $5.9 billion to $5.95 billion for the full year, which is $350 million above our prior guidance and reflects 19% growth year over year at the midpoint. ... Q1 2019 Earnings Call Transcript. Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q1 2020 Earnings Call Transcript Alexion Pharmaceuticals (ALXN) Q1 profit drops 5% but beats estimates Alexion (ALXN) to acquire Portola (PTLA) for $1.44 billion And by the way, the second one, which was similar to the question that Geoffrey Porges asked on ULTOMIRIS subcu, as I mentioned, we do believe, emphatically, that's an important offering to build out more of a portfolio of choices that are ULTOMIRIS based for patients. Monday, 1 February 2021 zacks. We also remain on track to initiate a Phase III program with AG10 or ALXM2060 in ATTR cardiomyopathy by the end of this year in Japan, rounding out our current cardiology programs. Your line is now open. As John mentioned earlier, we received regulatory approval for atypical HUS in Japan in September, and the local team is quickly progressing with launch activities. I was wondering, John, if you can just confirm that the point estimate for the is better than 0.9, and that the confidence intervals are not particularly wide. We're making progress with the launch of the 100-milligram per milliliter higher concentration of ULTOMIRIS in the U.S., reducing the average annual infusion time by approximately 60% for patients. 24 July 2019: CEO Ludwig … Alexion Q4 2019 Earnings Call Transcript Acquisition rationale Portola’s Andexxa drug is used in the major and life-threatening bleeds including gastrointestinal and intracranial hemorrhage and it has got a strong patent and regulatory exclusivity through 2030 in the US and 2028 in … Our COVID-19 305 study, as I said, is enrolling, and we should have interim data in the first part of 2021. So, on the question about the 30% that -- well, roughly 30%, let's say, that have not converted to ULTOMIRIS for PNH, especially, and that's more a story about there's a long tail of PNH prescribing. 6 May 2020 : Q1 2020 Earnings Call Transcript Q4 2019. Aradhana Sarin -- Chief Financial Officer. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. We continue to build upon this success with additional ULTOMIRIS development programs and our third-generation C5 inhibitor, 1720. Reddit 1 hour Del Taco Restaurants, Inc. (TACO) CEO John Cappasola on Q4 2020 Results – Earnings Call Transcript Seeking Alpha 2 hours Clarus Corporation (CLAR) Management on Q4 2020 Results – Earnings Call Transcript Seeking Alpha 2 hours Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q3 2021 … 30 January 2020: Q4 2019 Earnings Call Transcript Q3 2019. We're over 30% enrolled now. So even the impact that we've seen is not just SOLIRIS patients alone. As you heard on our investor day, we see ANDEXXA as one of the key drivers of Alexion's midterm growth potential. But we do think it's a very important addition of optionality for patients to have. Q4 Earnings financial workbook 32.4 KB. And so, what we continue to monitor is, again, making sure that we've got the capabilities in place to be successful with or without COVID. And each of these pieces are essential to deliver the full value of ANDEXXA. Yes. 06, 2020Corporate Participants: Chris Stevo — Head of Investor Relations. Here Are 3 Game-Changing Stocks to Buy, Got $1,000? Image source: The Motley Fool. | Source: Seeking Alpha AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 | Price: Free! As we have shared, with our focused rare disease expertise, we have the team and the resources to deliver on the promise of our broad and diverse pipeline and to be the leader in rare disease. The once-weekly ULTOMIRIS subcutaneous program for PNH and atypical HUS remains on track for filing in the third quarter of next year. The expansion of our C5 business began with Neurology, which is now the largest franchise in the U.S. in terms of both revenues and patient volumes. Alexion to Report Q4 Earnings: What's in the Cards? And we look forward to expanding the ULTOMIRIS franchise with the potential once-weekly subcutaneous formulation with the goal to provide an alternative choice to patients who prefer to self-administer. Before the end of 2020, we expect an additional four clinical programs to initiate and 2 INDs to be filed with ALXN1820 expected soon. Aradhana Sarin — Executive Vice President, Chief Financial Officer. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Good questions. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Thanks. View Presentation 3.3 MB. Find the latest Earnings Report Date for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. Thank you for joining us on today's call to discuss Alexion's performance for the third-quarter 2020. 31 July 2020: Q2 2020 Earnings Call Transcript Q1 2020. 24 July 2019: CEO Ludwig … You can access the webcast slides that will be presented on this call and other earnings materials by going to the events section of our investor relations page on our website. 30 October 2020: Q3 2020 Earnings Call Transcript Q2 2020. We anticipate multiple pivotal readouts for some of these key programs over the next 12-plus months. Would love to get your thoughts there. However, in our preclinical experiments using a rabbit model of geographic atrophy, we found that 2040 is actually -- has a high infinity for melanin in the back of the eye where it's concentrated and essentially allows for our prolonged distribution to the retina, which is very important in treating geographic atrophy since the disease starts with the choroid and the retinal pigment epithelium which provides nutritional support to the photoreceptors. We do plan to attempt to extrapolate the data from this program, which is being conducted in patients with PNH. As a biotech company, Alexion is uniquely positioned within the industry with a unique set of rare disease tailored capabilities. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q4 FY07 Earnings Call February 14, 2008 11:00 AM ET Executives. So, in PNH, there's 30% of patients that haven't switched to ULTOMIRIS. Contributor. So, we've seen an uptick in enrollment. And so that's why we're taking 2040 based on that rabbit model. Logo of jester cap with thought bubble with words 'Fool Transcripts' below it. Thank you. As of the end of the quarter, we have repurchased $434 million in shares in 2020, leaving us well within sight of our target of $500 million to $550 million for the year. But I think, overall, we take that as a very encouraging sign about the strength, first of all, of complement as a key part of the underlying pathophysiology. 30 January 2020: Q4 2019 Earnings Call Transcript Q3 2019. I also think that there may be patients that say that, for their home-based treatment, that that's the best option, subcutaneous and perhaps not once every two months, which for the majority of patients, we believe will be the key profile that they want. Expanded cross-functional teams are already deployed against many of these target accounts, and more will follow as we make progress in fully deploying our new mix of field-facing teams and enhanced capabilities. Non-GAAP EPS is expected to be between $11.70 and $12. Building on our leadership and complement and diversifying beyond C5, 2021 will be an exciting year for Alexion. And we expect to ultimately expand our unique target market to approximately 20,000 patients with the opportunity to move earlier in the patient journey. Given the large number of gMG patients in the U.S. and the remaining unmet needs many of these patients face, we believe new entrants have the possibility to expand the overall treated patient population and to facilitate disruption of earlier line, often cyclical treatment regimens. We're at the top of the hour. Jan 12, 2021 at 7:30 AM EST ... Alexion Pharmaceuticals, Inc. First Quarter 2020 Results. That's critically important in the complex institutions that we're focused on to make sure that you've got bleed protocols in place, formulary acceptance, and ultimately, demand generation, which is the second pillar. I'm pleased to share our third-quarter performance today. What do you think will happen in the U.S. once COVID subsides? Guidance for our metabolic business is now $835 million to $845 million, and we expect ANDEXXA revenues to be $65 million to $70 million in the second half of 2020. So, there's no issue there. While new patient additions have slowed from pre-COVID levels, we do continue to see balanced growth across both indications, and our teams are focused on continuing to pivot to new ways of working in light of the pandemic. The Phase III program for danicopan 2040 will be starting this quarter. And first, I would just remind everyone that this is our first full quarter of having ANDEXXA because the deal closed at the beginning of July. In addition to navigating reimbursement, OneSource helps facilitate sharing infusion site information with HCPs and patients. I really want to thank all my Alexion colleagues, again, for their hard work and needless to say that this team has been delivering quarter after quarter, and we plan to continue to do so. Finally, our OneSource organization in the U.S. provides trusted and consistent support services for patients. We remain focused on executing against our value-creation strategy and believe in our trajectory toward future growth. ALXN earnings call for the period ending March 31, 2019. So we are, I must say, pleased, certainly in the short-term with the fact that we continue to grow, and we definitely have the same remaining persistent ambition with 4x Neurology growth in the U.S. in the longer term. And then, lastly, do you intend to study subcu in MG and NMO? Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q2 2019 Earnings Call Jul 24, 2019, 8:00 a.m. And so, we look at that as that could be one example of the fact that first evidence that patients may queue up during the COVID shutdowns and then what you have is when things go off, you can have a higher volume during the decline period. Could you just sort of clarify that? Non-GAAP third quarter EPS was $3.24, growing 16% year over year. We're continuing our pursuit of U.K. reimbursement expansion to intracranial hemorrhages as well as reimbursement in Germany. Prepared Remarks: Operator. 30 October 2020: Q3 2020 Earnings Call Transcript Q2 2020. And as I had mentioned, we're mobilizing a lot more virtual promotional effectiveness, technology-based training of our teams. 30 January 2020: Q4 2019 Earnings Call Transcript Q3 2019. We see this goal as achievable even as new products come to market. Within the third quarter, PNH in Germany reached over 70% conversion of SOLIRIS patients to ULTOMIRIS, rounding out our top three markets to have achieved this ULTOMIRIS launch ambition. This article is a transcript of this conference call produced for The Motley Fool. But there's -- they're obviously very different disease states. We continue to innovate for patients to attempt to improve their holistic treatment experience. I just have two and they're probably for Brian. Logo of jester cap with thought bubble. As previously discussed, we continue to monitor the impact of the following as the COVID-19 situation evolves globally, including: access to medical care around the world, compliance rates across our indications, queue of new patient starts, and U.S. payer mix given fluctuating unemployment rates. So that's just one of many examples that we're putting in place. This revised guidance reflects the continued strength we have seen in the business and our fourth quarter outlook, including compliance rates continue to be strong across indications and slightly above expectations; continued strong conversion to ULTOMIRIS and the corresponding price headwinds that conversion implies; and increased demand for ANDEXXA.
Wirtschaftsministerium Nrw überbrückungshilfe, Annett Hofmann Uniklinik Dresden, B1 Stau Aktuell, Little Tikes Piano Songs, Bsv Live Tv, Fisher Price Mobile Anleitung, özlem Karabay Kimdir, Astrazeneca Aktie Usd, Bistum Eichstätt Dekanate, Ridderskamp Und Hahn Stellenangebote, Georg Jensen Damask Sale, Autohaus Bamberg Gebrauchtwagen,
Neue Kommentare